Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NLS Pharmaceutics Ltd. - Common Shares (NQ:NLSP)

2.320 +0.240 (+11.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NLS Pharmaceutics Ltd. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Crude Oil Moves Lower; NLS Pharmaceutics Shares Jump
Via Benzinga
Exposures Fossil Fuels
Tivic Health Systems (TIVC) Stock Pops Another 39%
Tivic Health Systems stock is up on Monday with heavy trading of TIVC shares as recent volatility continues for the company's units. 
Via InvestorPlace
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
NLS Pharmaceutics stock is up on Monday after the company provided NLSP investors with details on a merger deal with Kadimastem. 
Via InvestorPlace
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge
Via ACCESSWIRE
NLS Pharmaceutics Announces Registered Direct Offering
Via ACCESSWIRE
Why Is NLS Pharmaceutics (NLSP) Stock Up 163% Today?
NLS Pharmaceutics stock is up on Tuesday with heavy trading of NLSP shares despite a lack of news from the company this morning. 
Via InvestorPlace
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments
Via ACCESSWIRE
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
Via ACCESSWIRE
PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML
Palantir stock is on the rise Thursday as PLTR investors react to a new $19 million contract for the big data and AI company. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Dow Edges Lower; US Current Account Deficit Widens In Q1
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today?
NLS Pharmaceutics stock is down on Thursday as shares of NLSP come off of a recent rally that was fueled by heavy trading on Tuesday. 
Via InvestorPlace
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Thursday and we have all the hottest news behind these movements this morning! 
Via InvestorPlace
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
US Stocks Mixed; Retail Sales Increase 0.1% In May
Via Benzinga
Why Is Quantum (QMCO) Stock Down 32% Today?
Quantum stock is down on Tuesday as investors in QMCO shares react to the company's earnings report for fiscal 2024 this morning. 
Via InvestorPlace
Why Is Aerwins Technologies (AWIN) Stock Down 54% Today?
Aerwins Technologies stock is falling hard on Tuesday as investors in AWIN shares prepare for them to be delisted this morning. 
Via InvestorPlace
Why Is Actelis Networks (ASNS) Stock Up 144% Today?
Actelis Networks stock is up with heavy trading of ASNS shares after signing Carahsoft Technology as a new supply partner. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning! 
Via InvestorPlace
Why Chegg Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Via Benzinga
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
Via ACCESSWIRE
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
Via ACCESSWIRE
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
Via ACCESSWIRE
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
Via ACCESSWIRE
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
Via ACCESSWIRE
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
Via ACCESSWIRE
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.